The complement inhibitors are a class of drugs that inhibit the complement system, which is part of the immune system. The complement system helps antibodies and phagocytic cells to clear microbes and damaged cells from the body.
Global Complement Inhibitors Market can be antibodies or small molecules that selectively inhibit one or more components of the complement system. They are widely used for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and anti-acetylcholine receptor (AchR) antibody-positive myasthenia gravis.
The Global Complement Inhibitors Market is estimated to be valued at USD 85.10 Billion in 2024 and is expected to reach USD 236.11 Billion by 2031, growing at a compound annual growth rate (CAGR) of 15.7% from 2024 to 2031.
Key players operating in the Global Complement Inhibitors are Alexion Pharmaceuticals, Amgen, Apellis Pharmaceuticals, Achillion Pharmaceuticals and Ra Pharmaceuticals. Alexion Pharmaceuticals currently dominates the market with its blockbuster drugs Soliris and Ultomiris approved for PNH and aHUS indications.
The demand for complement inhibitors drugs is increasing rapidly mainly due to rising prevalence of complement-mediated diseases and limited treatment options. According to studies, over 8,000-10,000 people worldwide are diagnosed with PNH each year. Atypical HUS affects approximately 1 to 2 individuals per million people annually.
Advancements in understanding the role of complement system in various diseases has accelerated research activities for developing novel and selective complement inhibitors. Several biotechs are exploring complement pathways for developing therapies for inflammatory disorders, AMD and transplant rejection.
Market Trends
Oral drugs are gaining significant attention as an alternative to intravenous drugs due to better safety profile and convenience of administration. Apellis Pharmaceuticals’ oral C3 inhibitor, pegcetacoplan is under priority review by FDA for PNH.
Targeting specific complement pathways/components is a key focus area to address safety issues related to broad complement inhibitors. Ra Pharmaceuticals is developing a next-gen C5 monoclonal antibody with potentially safer profiles compared to current drugs.
Market Opportunities
Emerging market like China, India, Brazil and Mexico are expected to provide high growth opportunities driven by growing healthcare investments, economic developments and increasing disease burden.
Initiating clinical studies and collaborations to explore efficacy of complement inhibitors in other indications with high unmet need like AMD, COVID-19 and transplant rejection can further expand existing market sizes.
Impact of COVID-19 on Global Complement Inhibitors Market Growth
The COVID-19 pandemic has negatively impacted the growth of the global complement inhibitors market. During the initial months of the outbreak in 2020, restrictions imposed by various governments globally led to disruptions across the supply chain and production facilities. This caused a decrease in sales revenue as well as manufacturing output. However, as the medical community began to understand the severity of the novel coronavirus infection and its potential to cause cytokine storm in severe cases, complement inhibitors emerged as a treatment option. This boosted demand and provided some impetus for market recovery towards the end of 2020 and in 2021.
With COVID-19 projected to remain a global health challenge in the coming years, biopharmaceutical companies are ramping up their research and production capacities to ensure adequate supply of complement inhibitors. Several clinical trials are underway to evaluate the efficacy and safety of complement inhibitor drugs such as ravulizumab, eculizumab and fidanacizumab in controlling SARS-CoV-2-induced cytokine release syndrome and hyperinflammation. This is expected to aid market expansion over the forecast period. However, factors such as high treatment costs and need for intravenous administration pose challenges. Virtual drug launches and online promotional activities replaced traditional in-person interactions to counter the impact of restrictions imposed due to COVID-19.
North America accounts for the largest share of the global complement inhibitors market in terms of value owing to strong research activities in this area as well as presence of major companies. Europe follows North America in terms of market size. Asia Pacific is anticipated to be the fastest growing regional market supported by rising healthcare spending, improving access to advanced therapeutics and increasing COVID-19 cases especially in populous nations like China and India.
Geographical Regions Concentrated for Global Complement Inhibitors Market
The global complement inhibitors market in terms of revenue generation is primarily concentrated in North America, led by United States. This is due to a well-established healthcare infrastructure, high per capita income enabling access to expensive treatments, and presence of leading market players like Alexion Pharmaceuticals and Apellis Pharmaceuticals. Europe represents the second largest regional market driven by factors such as growing research on complement therapeutics, rising prevalence of autoimmune and inflammatory diseases, and availability of reimbursements facilitating affordability. Within Europe, major contributors include countries like Germany, United Kingdom and France.
Fastest Growing Region for Global Complement Inhibitors Market
Asia Pacific region is poised to witness the highest CAGR during the forecast period among all geographical segments in the global complement inhibitors market. This growth can be attributed to rising geriatric population base susceptible to age-related conditions, increasing healthcare expenditure in Asia's emerging economies including India and China, growing awareness about immunotherapies and complement-based treatment options. Further, supportive regulatory guidelines and presence of leading companies focused on enhancing regional access through product launches are boosting adoption. Positive clinical research outcomes validating complement inhibitors for COVID-19 treatment are also creating new opportunities for market expansion across Asia Pacific.
Get more insights on: Global Complement Inhibitors Market
Get this Report in Japanese Language: 世界の補体阻害剤市場
Get this Report in Korean Language: 글로벌 보체 억제제 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)